As relevant examples reviewed in [5], pharmacological drugs for treatment of patients with asthma and/or chronic obstructive pulmonary disease (COPD) were developed to include both β2-agonists to relax airway smooth muscle constriction and muscarinic receptor antagonists to block M3 receptors.